Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

So if $10 is the proper valuation (pre-FED

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Jaylimab Member Profile
 
Followed By 2
Posts 63
Boards Moderated 0
Alias Born 05/17/20
160x600 placeholder
CytoDyn gets Brazil regulatory clearance for late-stage COVID-19 trial Seeking Alpha - 8/3/2021 6:16:12 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 8/2/2021 5:19:26 PM
WSGF - World Series of Golf Inc VERY BULLISH Signal Continues InvestorsHub NewsWire - 8/2/2021 9:45:22 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 8/2/2021 7:19:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2021 7:16:50 AM
Annual Report (10-k) Edgar (US Regulatory) - 7/30/2021 5:13:13 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/30/2021 4:07:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2021 4:02:51 PM
IQST Anticipated To Report Q2 80 Plus Percent Revenue Growth Triggering Possible Investor Enthusiasm Reboot That Took PPS To $2.00 Earlier This Year InvestorsHub NewsWire - 7/30/2021 11:09:52 AM
Activist investor group pushing for CytoDyn board overhaul Seeking Alpha - 7/28/2021 9:36:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2021 5:26:03 PM
Proxy Statement - Contested Solicitations (preliminary) (prec14a) Edgar (US Regulatory) - 7/20/2021 5:06:54 PM
CytoDyn to hold webcast on July 22 to discuss cancer, NASH, and COVID-19 trials Seeking Alpha - 7/20/2021 12:01:04 AM
CytoDyn reports preliminary leronlimab results from mid-stage breast cancer study Seeking Alpha - 7/19/2021 6:19:22 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/12/2021 6:31:24 PM
CytoDyn advances leronlimab into Phase 2 stage in breast cancer trial Seeking Alpha - 7/12/2021 7:10:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/9/2021 5:12:45 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 7/7/2021 4:17:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/6/2021 4:31:55 PM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
CytoDyn submits dose justification report to FDA for leronlimab BLA in HIV Seeking Alpha - 7/2/2021 1:55:53 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 7/1/2021 5:28:14 PM
CLNV Targets $300 Billion Food Packaging Industry With Environmentally Sustainable Biodegradable Alternative InvestorsHub NewsWire - 6/22/2021 9:55:37 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
CytoDyn posts preliminary results from COVID-19 long-haulers study Seeking Alpha - 6/21/2021 9:38:56 AM
Jaylimab   Thursday, 07/02/20 01:54:32 PM
Re: Evil Rabbit post# 90130
Post # of 177284 
So if $10 is the proper valuation (pre-FED Approval for COVID)...then we should go back up (currently at $6) to near $10 near term (next week or 2) prior to potential FED approval (August). Correct?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences